InvestorsObserver is giving Kindred Biosciences Inc (KIN) an Analyst Rating Rank of 69, meaning KIN is ranked higher by analysts than 69% of stocks. The average projection by analysts for KIN is $11.75 over the next 12 months and analyst’s classify the stock as a Strong Buy
Why are Analyst Ratings Important?
Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve.
Investors Observer combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.
What's Happening With Kindred Biosciences Inc Stock Today?
Kindred Biosciences Inc (KIN) stock is trading at $4.20 as of 2:16 PM on Friday, Aug 28, an increase of $0.25, or 6.33% from the previous closing price of $3.95. The stock has traded between $3.96 and $4.47 so far today. Volume today is elevated. So far 790,461 shares have traded compared to average volume of 243,454 shares.
